ArticleCancers2022

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany.

Peter Mohr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.